TY - JOUR
T1 - Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients
AU - Hu, Bei
AU - Lin, Xiao
AU - Lee, Hans C.
AU - Huang, Xuelin
AU - Tidwell, Rebecca S.Slack
AU - Ahn, Kwang Woo
AU - Hu, Zhen Huan
AU - Jabbour, Elias
AU - Verstovsek, Srdan
AU - Ravandi, Farhad
AU - Garcia-Manero, Guillermo
AU - Kharfan-Dabaja, Mohamed A.
AU - Hossain, Nasheed M.
AU - Marks, David I.
AU - Kamble, Rammuriti T.
AU - Inamoto, Yoshihiro
AU - Kindwall-Keller, Tamila
AU - Saad, Ayman
AU - Litzow, Mark R.
AU - Savani, Bipin N.
AU - Hale, Gregory A.
AU - Bacher, Ulrike
AU - Gerds, Aaron T.
AU - Liesveld, Jane L.
AU - Ustun, Celalettin
AU - Olsson, Richard F.
AU - Daly, Andrew
AU - Grunwald, Michael R.
AU - Solh, Melhem
AU - DeFilipp, Zachariah
AU - Aljurf, Mahmoud
AU - Wirk, Baldeep
AU - Akpek, Gorgun
AU - Nishihori, Taiga
AU - Cerny, Jan
AU - Seo, Sachiko
AU - Hsu, Jack W.
AU - Champlin, Richard
AU - de Lima, Marcos
AU - Alyea, Edwin
AU - Popat, Uday
AU - Sobecks, Ronald
AU - Scott, Bart L.
AU - Kantarjian, Hagop
AU - Cortes, Jorge
AU - Saber, Wael
N1 - Publisher Copyright:
© 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020
Y1 - 2020
N2 - While TKI are the preferred first-line treatment for chronic phase (CP) CML, alloHCT remains an important consideration. The aim is to estimate residual life expectancy (RLE) for patients initially diagnosed with CP CML based on timing of alloHCT or continuation of TKI in various settings: CP1 CML, CP2 + [after transformation to accelerated phase (AP) or blast phase (BP)], AP, or BP. Non-transplant cohort included single-institution patients initiating TKI and switched TKI due to failure. CIBMTR transplant cohort included CML patients who underwent HLA sibling matched (MRD) or unrelated donor (MUD) alloHCT. AlloHCT appeared to shorten survival in CP1 CML with overall mortality hazard ratio (HR) for alloHCT of 2.4 (95% CI 1.2–4.9; p =.02). In BP CML, there was a trend toward higher survival with alloHCT; HR = 0.7 (0.5–1.1; p =.099). AlloHCT in CP2 + [HR = 2.0 (0.8–4.9), p =.13] and AP [HR = 1.1 (0.6–2.1); p =.80] is less clear and should be determined on a case-by-case basis.
AB - While TKI are the preferred first-line treatment for chronic phase (CP) CML, alloHCT remains an important consideration. The aim is to estimate residual life expectancy (RLE) for patients initially diagnosed with CP CML based on timing of alloHCT or continuation of TKI in various settings: CP1 CML, CP2 + [after transformation to accelerated phase (AP) or blast phase (BP)], AP, or BP. Non-transplant cohort included single-institution patients initiating TKI and switched TKI due to failure. CIBMTR transplant cohort included CML patients who underwent HLA sibling matched (MRD) or unrelated donor (MUD) alloHCT. AlloHCT appeared to shorten survival in CP1 CML with overall mortality hazard ratio (HR) for alloHCT of 2.4 (95% CI 1.2–4.9; p =.02). In BP CML, there was a trend toward higher survival with alloHCT; HR = 0.7 (0.5–1.1; p =.099). AlloHCT in CP2 + [HR = 2.0 (0.8–4.9), p =.13] and AP [HR = 1.1 (0.6–2.1); p =.80] is less clear and should be determined on a case-by-case basis.
KW - Chronic myeloid leukemia
KW - allogeneic stem cell transplant
KW - tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85089288816&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089288816&partnerID=8YFLogxK
U2 - 10.1080/10428194.2020.1783444
DO - 10.1080/10428194.2020.1783444
M3 - Article
C2 - 32662346
AN - SCOPUS:85089288816
SN - 1042-8194
SP - 2811
EP - 2820
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
ER -